Research programme: low dose naltrexone-based therapeutic - Premier Biomedical

Drug Profile

Research programme: low dose naltrexone-based therapeutic - Premier Biomedical

Alternative Names: Feldetrex®

Latest Information Update: 18 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Premier Biomedical
  • Class Analgesics; Cyclopropanes; Morphinans; Small molecules
  • Mechanism of Action Neurotransmitter modulators; Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research Brain injuries; Drug abuse; Fibromyalgia; Multiple sclerosis; Neuropathic pain

Most Recent Events

  • 09 May 2017 Feldetrex™ is available for partnering.
  • 26 Jan 2016 Premeir Biomedical files for provisional patent application for second drug
  • 15 Dec 2015 Early research in Neuropathic pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top